Company:  GENPREX, INC. (GNPX)
Form Type:  10-Q
Filing Date:  5/15/2019 
CIK:  0001595248 
Address:  1601 TRINITY STREET, BLDG. B
SUITE 3.322
 
City, State, Zip:  AUSTIN, Texas 78712 
Telephone:  512-537-7997 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$1.63  
Change: 
-0.1254 (-7.17%)  
Trade Time: 
09:35 AM EST  
Market Cap: 
$25.35M
Trade GNPX now with 

© 2019  
Description of Business
Genprex(TM) is a clinical stage gene therapy company developing a new approach to treating cancer, based upon our novel proprietary technology platform, including our initial product candidate, Oncoprex(TM) immunogene therapy, or Oncoprex. Our platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.
Register and access this filing in:     
  FORM 10-Q
    PART I - FINANCIAL INFORMATION
      Item 1. Financial Statements.
        BALANCE SHEET
        INCOME STATEMENT
        CASH FLOW
        NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
          Note 9-Subsequent Events
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 4. Controls and Procedures. Disclosure Controls and ...
    PART II - OTHER INFORMATION
      Item 1. Legal Proceedings
      Item 1A. Risk Factors
      Item 2. Unregistered Sales of Equity Securities and Use of ...
      Item 5. Other Information
      Item 6. Exhibits
    INDEX TO EXHIBITS
    SIGNATURES
  EXHIBIT 31.1
    CERTIFICATION PURSUANT TO
  EXHIBIT 31.2
    CERTIFICATION PURSUANT TO
  EXHIBIT 32.1
    CERTIFICATIONS OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION ...